Abstract: A nitrogen-containing fused ring derivative inhibitor, a preparation method therefor and the use thereof. The present invention particularly relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an NK inhibitor in the treatment of depression, anxiety, schizophrenia, sex hormone-dependent diseases and other related diseases. The various substituents in general formula (I) have the same definition as that in the description.

Abstract: The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.

Abstract: Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.

Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Abstract: Provided are a pyrazole-containing polycyclic derivative inhibitor, a preparation method therefor and an application thereof. In particular, provided are a compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and an application thereof as a P2X3 inhibitor in treatment of P2X3 receptor function disorders, particularly in treatment of neurogenic diseases, wherein the substituents in the formula (I) are the same as those in the description in definition.

Abstract: A biphenyl derivative inhibitor represented by general formula (Ib) and use in the preparation of medicaments for treating cancer, infectious diseases, and autoimmune diseases.

Abstract: Provided are an FGFR4 inhibitor with the structure of formula (I) and a preparation method and use thereof. The series of compounds of formula (I) have a very strong inhibitory effect on the FGFR4 kinase activity, and have a very high selectivity; and the same can be widely used to prepare drugs for treating cancers, in particular, liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and it is expected that the same can be developed into a new generation of FGFR4 inhibitor drugs.

Abstract: Provided are an anti-B7-H4 antibody-drug conjugate and medicinal use thereof. Specifically, provided is an anti-B7-H4 antibody or antigen-binding fragment thereof, a humanized antibody comprising the CDR region of the anti-B7-H4 antibody, and antibody-drug conjugate thereof or pharmaceutically acceptable salt or solvent compound thereof, and the aforesaid antibody-drug conjugate thereof or pharmaceutical composition of a pharmaceutically acceptable salt or solvent compound thereof, and use thereof as an anti-cancer drug, particularly the use in the preparation of a drug for treating diseases or disorders having high expression of B7-H4.

Abstract: Provided is a modifier of a four-membered ring derivative, a preparation method and application thereof. In particular, provided is a compound represented by the general formula (IX-A), a preparation method thereof, a pharmaceutical composition containing the compound, and a use thereof as a G protein-coupled receptor modulator in the treatment or prevention of central nervous system diseases and/or mental diseases. The definition of each substituents in the general formula (IX-A) is same as the definition in the specification.

Abstract: The present invention relates to heteroaromatic derivatives for use as a regulator, a preparation method therefor and a use thereof. In particular, disclosed are compounds represented by general formula (I), preparation methods therefor, pharmaceutical compositions comprising said compounds, and a use thereof as Janus kinase inhibitors in treating inflammatory diseases and tumor-related diseases.

Abstract: The present invention relates to an indole derivative-containing inhibitor, a preparation method therefor and an application thereof, and in particular, to a compound as represented by general formula (Ia), a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in treating related diseases such as cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease, and AIDS as a kinase inhibitor, especially as a receptor tyrosine kinase inhibitor (TKI), more specifically, as an EGFR or HER2 inhibitor. The compound exhibits good inhibitory activity in EGFR and HER2 20 exon mutations.

Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)actylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: Provided are an inhibitor containing a bicyclic derivative, a preparation method therefor and the use thereof. In particular, involved are a compound shown by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an RET inhibitor in the treatment of cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases, AIDS, and other related diseases, wherein each substituent in general formula (I) has the same definition as that given in the description.

Abstract: Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis.

Abstract: Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. In particular, disclosed are a compound as represented by general formula (I), a preparation method for the compound and a pharmaceutical composition containing the compound, and the use thereof as a KRAS G12C mutation inhibitor in treatment of diseases or symptoms such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer, wherein the definitions of substituents in general formula (I) are the same as those in the description.

Abstract: A series of pharmaceutical compositions containing polypeptide dual agonist compounds and pharmaceutically acceptable salts thereof, wherein same have dual agonist effects on a human glucagon-like peptide-1 (GLP-1) receptor and a human blood glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used for treating non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases.

Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Abstract: Provided are an FGFR4 inhibitor with the structure of formula (I) and a preparation method and use thereof. The series of compounds of formula (I) have a very strong inhibitory effect on the FGFR4 kinase activity, and have a very high selectivity; and the same can be widely used to prepare drugs for treating cancers, in particular, liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and it is expected that the same can be developed into a new generation of FGFR4 inhibitor drugs.

Abstract: Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.